The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 353.60
Bid: 354.80
Ask: 355.40
Change: 0.00 (0.00%)
Spread: 0.60 (0.169%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 353.60
QQ. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Fourth Quarter Trading Update

20 Apr 2022 07:00

RNS Number : 6600I
QinetiQ Group plc
20 April 2022
 

News release

 

QinetiQ Group plc

Fourth Quarter Trading Update

20 April 2022 - QinetiQ Group plc ("QinetiQ" or "the Group") today issues a trading update covering its fourth quarter to 31 March 2022.

Strong operational performance in fourth quarter - ahead of full year guidance

Through continued disciplined execution of our strategy, the Group has delivered strong operational performance through the fourth quarter. Today we are pleased to announce that we expect our results for the full year to 31 March 2022 to be marginally ahead of our previous guidance and current market consensus expectations.

Full year order intake has been very strong at more than £1.2bn and, subject to audit, we expect to deliver c.5% revenue growth on an organic basis with underlying operating profit of at least £135m. Operating cash flow has been excellent and we retain a strong balance sheet with net cash at 31 March 2022 of c.£225m.

Our strong performance has been driven by significant growth in EMEA Services, partially offset by the slower recovery in Global Products. We saw continued excellent growth in Australia and the UK driven by good programme execution and delivery across all our major contracts. US revenue performance recovery was slower than expected, with the second half in line with the first half, largely due to the US defence budget being constrained by the extended Continuing Resolution. However, we secured 20% year-on-year growth in order intake which, coupled with our new leadership team, provides a strong foundation for the delivery of our US growth strategy. The complex project contract is now closed and the financial impact remains the £14.5m write-down fully contained in our first half results.

We retain our medium to long-term guidance: we are targeting mid-single digit percentage compound annual organic revenue growth over the next five years, with strategic acquisitions further enhancing this growth. We are targeting a long-term operating profit margin of 12-13%, although in the short-term we anticipate margins being c.100bps lower, driven by inflationary pressures and continued investment. Capital expenditure for FY23 is expected to be at the upper end of the £90m to £120m per annum range, consistent with our previous guidance.

Steve Wadey, Group Chief Executive Officer said:

"I am extremely proud of how our people have continued to deliver critical defence and security capabilities for our customers, despite the ongoing challenges of the pandemic. Recent world events have reinforced the long-term needs of our customers, including capabilities utilising differentiated technology, test and training solutions which are directly aligned with our strategy. With a clear focus on disciplined execution of our strategy, increasing demand for our solutions and good revenue coverage, we have positive momentum to deliver sustainable growth in the coming years and are maintaining expectations for Group performance."

Investor seminar 27 April 2022

We are hosting an investor seminar on 27 April 2022 at The Smith Centre at The Science Museum, Exhibition Road, South Kensington, London, SW7 2DD. The presentation will cover our global ambition with a particular focus on the US and Australia. You are invited to join us for lunch from 12.30pm BST to see a selection of our products and capabilities, as well as meeting the QinetiQ Leadership Team. The presentation will run 1.30-3.30pm BST and there will be an option to view online if you cannot join us in person. More information including how to register can be found on our website here:

https://www.qinetiq.com/en/investors/investor-seminars/delivering-global-growth

Preliminary results

We will announce our preliminary results on 19 May 2022. We will be hosting an in-person results presentation, details of which will be available on our website shortly at: www.QinetiQ.com/investors.

About QinetiQ

QinetiQ (QQ.L) is a leading science and engineering company operating primarily in the defence and security markets. We work in partnership with our customers to solve real world problems through innovative solutions delivering operational and competitive advantage. Visit our website www.QinetiQ.com. Follow us on LinkedIn and Twitter @QinetiQ. Visit our blog www.QinetiQ-blogs.com.

For further information please contact:

John Haworth, Group Head of Investor Relations:

+44 (0) 7920 545841

Lorna Cobbett, Citigate Dewe Rogerson (Media enquiries):

+44 (0) 7771 344781

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBLGDSSXBDGDC
Date   Source Headline
10th Feb 202111:32 amRNSDirector/PDMR Shareholding
8th Feb 20219:57 amRNSDirector/PDMR Shareholding
13th Jan 20217:00 amRNSThird Quarter Trading Update
12th Jan 20219:49 amRNSDirector/PDMR Shareholding
4th Jan 20217:00 amRNSQinetiQ wins £127m Typhoon contract through EDP
21st Dec 20204:44 pmRNSHolding(s) in Company
10th Dec 202010:28 amRNSDirector/PDMR Shareholding
3rd Dec 20201:00 pmRNSSale of OptaSense to Luna
24th Nov 20201:31 pmRNSDirector/PDMR Shareholding
20th Nov 202012:37 pmRNSDirector/PDMR Shareholding
20th Nov 202011:43 amRNSHolding(s) in Company
17th Nov 202011:16 amRNSDirector/PDMR Shareholding
12th Nov 20207:00 amRNSInterim Results
10th Nov 202010:47 amRNSDirector/PDMR Shareholding
12th Oct 202010:09 amRNSDirector/PDMR Shareholding
5th Oct 20209:10 amRNSHolding(s) in Company
30th Sep 20207:00 amRNSPre-close Trading update
21st Sep 20203:57 pmRNSDirectorate Change
10th Sep 202010:29 amRNSDirector/PDMR Shareholding
20th Aug 20202:14 pmRNSHolding(s) in Company
13th Aug 20204:47 pmRNSDirector/PDMR Shareholding
11th Aug 202011:56 amRNSDirector/PDMR Shareholding
10th Aug 202011:28 amRNSTotal Voting Rights
4th Aug 20203:59 pmRNSBlock Listing Application
31st Jul 202012:50 pmRNSTransfer of Treasury Shares & Total Voting Rights
14th Jul 20202:00 pmRNSResult of Annual General Meeting
14th Jul 20207:00 amRNSQ1 Trading Update and Acquisition of Naimuri
13th Jul 20203:51 pmRNSQinetiQ enters next phase of growth in the US
10th Jul 202011:52 amRNSDirector/PDMR Shareholding
1st Jul 202010:50 amRNSDirector/PDMR Shareholding
1st Jul 202010:49 amRNSTotal Voting Rights
1st Jul 202010:46 amRNSDirector/PDMR Shareholding
25th Jun 20207:00 amRNSDisposal of Boldon James to HelpSystems
23rd Jun 202011:46 amRNSDirector/PDMR Shareholding
12th Jun 202010:48 amRNSAnnual Financial Report
10th Jun 202012:31 pmRNSDirector/PDMR Shareholding
21st May 20207:00 amRNSPreliminary Results
19th May 20204:05 pmRNSDirectorate Change
12th May 202011:22 amRNSDirector/PDMR Shareholding
1st May 202011:16 amRNSBlock listing Interim Review
30th Apr 20207:00 amRNSAppointment of Broker
29th Apr 20204:17 pmRNSHolding(s) in Company
15th Apr 202010:35 amRNSDirector/PDMR Shareholding
1st Apr 20209:33 amRNSHolding(s) in Company
1st Apr 20207:00 amRNSTrading and COVID-19 update
20th Mar 202010:21 amRNSDirector/PDMR Shareholding
18th Mar 20202:13 pmRNSHolding(s) in Company
10th Mar 202011:13 amRNSDirector/PDMR Shareholding
11th Feb 202010:53 amRNSDirector/PDMR Shareholding
10th Feb 202012:14 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.